Research map: Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa

Back to the article

Papers in this map

  1. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa · Alexa B. Kimball · 2016 · 804 citations · Cited by this paper
  2. JAMA+ Trials Editor’s Choice for Clinical Trial of 2025 in JAMA Dermatology · 2026 · Related
  3. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials · Alexa B. Kimball · 2023 · 333 citations · Cited by this paper
  4. GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa · 2026 · Related
  5. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study · Alexa B. Kimball · 2015 · 201 citations · Cited by this paper
  6. Dyschromatosis and Blistering in a Young Male · 2026 · Related
  7. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials · Alexa B. Kimball · 2024 · 190 citations · Cited by this paper
  8. JAMA Dermatology · 2026 · Related
  9. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data · John W. Frew · 2019 · 59 citations · Cited by this paper
  10. Progression From Acute to Chronic Urticaria · 2026 · Related
  11. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis · Alexander C. Egilman · 2024 · 22 citations · Cited by this paper
  12. Characterizing Dermoscopic Features of Longitudinal Melanonychia in Skin of Color · 2026 · Related
  13. Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa · Amit X. Garg · 2025 · 14 citations · Cited by this paper
  14. Melasma · 2026 · Related
  15. Biosimilars and interchangeability: Regulatory, scientific, and global perspectives · Alper B. İskit · 2025 · 13 citations · Cited by this paper
  16. Error in Title · 2026 · Related
  17. Use, Spending, and Prices of Adalimumab Following Biosimilar Competition · Benjamin N. Rome · 2024 · 12 citations · Cited by this paper
  18. Early Respiratory Infection Burden and Atopic Dermatitis in Childhood · 2026 · Related
  19. Cost Effectiveness of Emollients in the Prevention of Relapses in Atopic Dermatitis · Elise Cabout · 2020 · 5 citations · Cited by this paper
  20. Commercial Price Variation for Common Dermatologic Procedures · 2026 · Related
  21. Value-Based Healthcare: A Primer for the Dermatologist · Deepak M.W. Balak · 2024 · 4 citations · Cited by this paper
  22. Efficacy of Biologics for Hidradenitis Suppurativa: A Network Meta Analysis and Meta Regression for Baseline Disease Severity · James P. Pham · 2026 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)